Lung cancer is the third most common cancer in the United States and is the leading cause of cancer related mortality for both men and women, with 171,500 new cases and 165,600 deaths projected for 1998 in this country. Although smoking cessation trends among adults may result in fewer lung cancer cases in the short to intermediate term, smoking rates among young adults seem to be on the rise. In addition, smoking rates in other parts of the world guarantee that lung cancer will remain a major public health problem worldwide for years to come. One reason for the poor rate of survival of individuals diagnosed with lung cancer is the frequently advanced stage of the disease upon presentation. Thus, there is a clear need to characterize markers associated with early-stage lung cancer to improve methods of diagnosis. Novel therapies for the treatment and prevention of the disease are also wanting. The mouse has been used to model human lung cancer extensively over the past several years in a variety of circumstances, including in spontaneous tumor models, chemically-induced models using a variety of agents, and in certain transgenic strains. Although these studies have confirmed that the mouse can be an adequate model of the early stages of human non-small cell lung cancer (NSCLC) (the predominant form of human lung cancer), the methods used in the derivation of these models (e.g., treatment with chemical carcinogens or transgenic expression of viral oncoproteins) and their limited stage of progression has lessened enthusiasm somewhat. This MMHCC team proposes to create novel mouse models of human NSCLC and to characterize these strains in a variety of ways directed toward their proper validation. The strains will harbor targeted activating mutations in the K-ras oncogene (frequently mutated in human NSCLC) and constitutive or conditional loss-of-function mutations in the lung tumor suppressor genes p53 and the Ink4A locus. Existing and future mouse models of NSCLC will be examined by histological analysis in consultation with a veterinary and human clinical pathologist. Mouse tumors will be subjected to extensive DNA and RNA analysis, in part with reference to known molecular changes in human NSCLC and in part in an effort to identify changes that can then be screened for in human tumor samples. The mouse models of NSCLC will be used in cigarette smoke exposure studies and will be used to evaluate investigative chemotherapeutic and chemopreventative agents. A genetic modifier screen will be performed as part of the characterization of one of these strains. Finally, these mouse lung cancer models will be used in the development of novel non-invasive imaging protocols for primary lung tumors and metastatic lesions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA084306-01
Application #
6039341
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (O3))
Program Officer
Marks, Cheryl L
Project Start
1999-09-30
Project End
2004-03-31
Budget Start
1999-09-30
Budget End
2000-03-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
Organized Research Units
DUNS #
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Li, Carman Man-Chung; Gocheva, Vasilena; Oudin, Madeleine J et al. (2015) Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes Dev 29:1850-62
Li, Carman Man-Chung; Chen, Guoan; Dayton, Talya L et al. (2013) Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes Dev 27:1557-67
Snyder, Eric L; Watanabe, Hideo; Magendantz, Margaret et al. (2013) Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell 50:185-99
Shaw, Alice T; Winslow, Monte M; Magendantz, Margaret et al. (2011) Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A 108:8773-8
Winslow, Monte M; Dayton, Talya L; Verhaak, Roel G W et al. (2011) Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473:101-4
Young, Nathan P; Crowley, Denise; Jacks, Tyler (2011) Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res 71:4040-7
Kirsch, David G; Grimm, Jan; Guimaraes, Alexander R et al. (2010) Imaging primary lung cancers in mice to study radiation biology. Int J Radiat Oncol Biol Phys 76:973-7
Young, Nathan P; Jacks, Tyler (2010) Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc Natl Acad Sci U S A 107:10184-9
Oliver, Trudy G; Mercer, Kim L; Sayles, Leanne C et al. (2010) Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 24:837-52
DuPage, Michel; Dooley, Alison L; Jacks, Tyler (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4:1064-72

Showing the most recent 10 out of 20 publications